Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow AtriCure, Inc.

Get SEC filing alerts via email and in your feed for AtriCure, Inc.

ATRC

AtriCure, Inc.

About AtriCure, Inc.

AtriCure, Inc. develops and markets medical devices for the surgical treatment of atrial fibrillation (Afib), left atrial appendage management (LAAM), and post-operative pain management. Its product portfolio includes radiofrequency and cryoablation systems, the AtriClip LAA exclusion device, and cryo nerve block probes. Serving cardiothoracic surgeons and electrophysiologists globally, AtriCure’s technologies offer clinically proven, less invasive solutions to improve patient outcomes and reduce stroke risk and post-surgical pain.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from AtriCure, Inc.

1
1
AtriCure, Inc. AtriCure Reports 14.3% Revenue Growth to $141.2 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
AtriCure, Inc. AtriCure Reports 14.9% Revenue Growth to $534.5 Million for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
AtriCure, Inc. AtriCure Reports 15.8% Revenue Growth to $134.3 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
AtriCure, Inc. AtriCure Reports 17.1% Revenue Growth to $136.1 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
AtriCure, Inc. AtriCure Reports $123.6 Million Revenue in Q1 2025, 13.6% Increase Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
AtriCure, Inc. AtriCure Reports 16.5% Revenue Growth to $465.3 Million for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
AtriCure, Inc. AtriCure Reports 17.9% Revenue Growth in Q3 2024, Net Loss Narrows

Via official filing (AI summary) | over 1 year ago | 0 comments